MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
This marks Glenmark's first synthetic decapeptide injectable approval
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
The company plans to enter the EU markets in FY22
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
Subscribe To Our Newsletter & Stay Updated
